FDA Waiting For EGFR Diagnostic Kit Data As Supplement To Vectibix BLA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
In what could signal a trend for targeted therapies, FDA concluded in its Vectibix review that the diagnostic test kit used to screen subjects for EGFR expression would need to be submitted as a supplement to the BLA